LSLaurent Siproudhis

Laurent Siproudhis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laurent Siproudhis has a total of 778 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Identification of the optimal medical and surgical management for patients with perianal fistulising Crohn's disease

    by Mathilde Laland, Marie François, Ferdinando D'AMico, Camille Zallot, Charlène Brochard, Marie Dewitte, Laurent Siproudhis, Laurent Peyrin‐Biroulet, Guillaume Bouguen

    Aim: The aim of our study was to assess the best medical and surgical approaches for perianal Crohn's disease (PCD) in order to identify an optimal combined medical and surgical treatment.Methods: Medical records of all patients with PCD treated with TNFα antagonists in two referral centres between 1998 and 2018 were reviewed. Predictors of long‐term outcomes were identified using a Cox proportional hazard model.Results: A total of 200 patients were included. Fifty‐three patients (26.5%) were treated with adalimumab and 147 (73.5%) with infliximab. A combination of TNFα antagonist with an immunosuppressant and the presence of proctitis were independently associated with fistula closure. Seton was placed in 127 patients (63.5%) before starting biological therapy. Eighty patients (40%) underwent additional perineal surgery. Prior PCD surgery, seton positioning, additional perineal surgery, and additional surgery within 52 weeks of anti‐TNFα treatment were associated with an increased rate of fistula closure. Finally, medical combination therapy (anti‐TNFα plus immunosuppressant) along with seton placement and additional surgery within 1 year was the best management for PCD patients (p = 0.02).Conclusion: Combined medical and surgical management is required for the treatment of PCD patients. Medical combination therapy associated with seton placement and additional surgery within 1 year is the best management for PCD patients.


  • Open Access

    P618 Treatment outcomes of patients with Crohn’s disease and complex perianal fistula in five European countries: the PREFACE retrospective study

    by M Ferrante, L Siproudhis, G Poggioli, M Reinshagen, S Milicevic, M Roset, N Bent-Ennakhi, R D’ambrosio, A Fernandez-Nistal, J Panes

    Presence of fistulas in Crohn’s disease (CD) is an indicator of poor prognosis; 20% of CD patients suffer from perianal fistula. There are few studies specifically designed to assess treatment outcomes in complex perianal fistula (CPF) in CD. This retrospective chart review study describes the outcomes of patients with CPF in CD in five European countries after medical and/or surgical treatment. Adult patients with CD receiving treatment for a new episode of CPF during the eligibility period (September 2011 to September 2014), in Belgium, France, Germany, Italy and Spain, were included. Index date was defined as date of any medical or surgical CPF treatment initiation. Data was collected from CD diagnosis to at least 3 years after index date (except for deceased or lost to follow-up patients) to describe patient characteristics and treatments used for all CPF episodes since CD diagnosis. Effectiveness outcomes were measured as remission rates based on Fistula Drainage Assessment (FDA) recorded in medical charts for fistula reported at index date (index fistula). Remission rates are expressed as percentage rates on patient level after 6- and 12-months follow-up period. For calculation of treatment outcomes, the most recent FDA prior to the respective timepoint was used. A total of 372 patients (51% male) with a mean (SD) age of 38 (13) were included by 31 sites. Median time since CD diagnosis was 7 years, and median length of follow-up was 6 years. A total of 498 CPFs were presented at index date and during FU period. Out of the 498 CPFs, 94% were treated with at least one surgical intervention (most frequent: 61% long-term seton placement, 51% surgical drainage) and 82% with at least one medical treatment (most frequent: 40% anti-TNFs, 33% antibiotics, 16% immunosuppressants). After 6 months the remission rate at patient level for index fistula was 28% and after 12 months 35%. Current standards of care achieved remission in one third of patients with CPF in CD over a period of one year. Improved therapeutic strategies and new treatment options are required to improve outcomes in this manifestation of CD.

  • Patients’ real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group

    by Maria Nachury, Yoram Bouhnik, Melanie Serrero, Jerome Filippi, Xavier Roblin, Julien Kirchgesner, Guillaume Bouguen, Denis Franchimont, Guillaume Savoye, Anthony Buisson, et al.


  • PGI12 Healthcare Resource Utilization Associated with Complex Perianal Fistula in Crohn's Disease in FIVE European Countries: The Preface Study, a Retrospective Chart Review

    by M. Ferrante, L. Siproudhis, G. Poggioli, M. Reinshagen, S. Milicevic, M. Roset, N. Bent-Ennakhil, R. D‘aMbrosio, A. Fernández, J. Panes

  • Improving the screening of precancerous anal lesions in high-risk subjects with normal cytology: A longitudinal cohort study using simple tests

    by Johanna Moreau, Laurent Siproudhis, Charlène Brochard, Sébastien Henno, Vincent Thibault, Emeric Boisteau, Claire Gouriou, Aurore Carlo, Annie Lion, Guillaume Bouguen, et al.


  • Dépistage du cancer de l’anus et des lésions précancéreuses du canal anal

    by L. Siproudhis, S. Henno

    Il existe aujourd’hui deux modalités de dépistage et de suivi des lésions de dysplasies et de cancer de l’anus. L’une est très consommatrice d’énergie et de temps (anuscopie haute résolution répétée), et l’autre est celle d’une approche minimaliste (anuscopie). La première expose à une mauvaise observance et de nombreux perdus de vue, la seconde à un diagnostic et une prise en charge trop tardifs (cancer invasif) quand la surveillance et le traitement de la dysplasie de haut grade peuvent apparaître des objectifs ambitieux mais cohérents.

  • Open Access

    Formations en proctologie : diversifier l’offre et la rendre lisible

    by L. Siproudhis

    Côlon & Rectum est la revue francophone de formation continue - médicale et chirurgicale - des maladies du côlon, du rectum et de l’anus.

  • Open Access

    Protocol of a multicentric prospective cohort study for the VALIDation of the IBD-disk instrument for assessing disability in inflammatory bowel diseases: the VALIDate study

    by C. Le Berre, A. Bourreille, M. Flamant, G. Bouguen, L. Siproudhis, M. Dewitte, N. Dib, E. Cesbron-Metivier, T. Goronflot, M. Hanf, et al.

    Background: Inflammatory Bowel Diseases (IBD) affect psychological, family, social and professional dimensions of patients’ life, leading to disability which is essential to quantify as part of Patient-Reported Outcomes (PROs) newly included in the targets to reach in IBD patients. Up to now, the IBD-Disability Index (IBD-DI) was the only validated tool to assess disability, but it is not appropriate for use in clinical practice. The IBD Disk was developed, a shortened and self-administered tool, adapted from the IBD-DI, in order to give immediate representation of patient-reported disability. However, the IBD Disk has not been validated yet in clinical practice. The aims of the VALIDate study are to validate this tool in a large population of IBD patients and to compare it to the already validated IBD-DI. Methods: The VALIDate study is an ongoing multicentric prospective cohort study launched in April 2018 in 3 French University Hospitals (Nantes, Rennes, Angers), with an objective to reach a sample of 400 patients over a period inclusion of 6 months. Each patient will fill in the two questionnaires IBD Disk and IBD-DI at baseline, then between 3 and 12 months later, during a follow-up visit. Clinical and socio-demographic data will also be collected. During these two consultations, gastroenterologists and patients will evaluate disease activity thanks to a semi-quantitative 4-grade scale, named respectively PGA (Physician Global Assessment) and PtGA (Patient Global Assessment). This cohort will allow to evaluate the validity of the IBD Disk with respect to the IBD-DI in order to generalize its use for clinical practice. Other psychometric criteria of the IBD Disk will also be analysed as its reliability or its discriminant capacity. Close attention will nonetheless be needed to minimize the number of lost to follow-up patients between baseline and follow-up. Discussion: The VALIDate study is the study designed to validate the IBD Disk, a visual tool easily useable in daily practice to assess disability in IBD patients. The results of this trial should enable the diffusion of this tool. Trial registration: The trial is registered in ClinicalTrials.Gov with registration number NCT03590639. First posted: July 18, 2018.


  • Définition et mesure de l’obstruction à la défécation

    by L. Siproudhis

    Le syndrome d’obstruction défécatoire est une situation peu satisfaisante à la fois pour les malades qui s’en plaignent et les médecins consultés. Les premiers ont des réticences à évoquer des symptômes jugés dégradants. Les seconds ont des difficultés de prise en charge liées à des stratégies peu différenciées (constipation). Cependant, une évaluation symptomatique précise (consistance des selles), un examen dynamique anorectal (anisme, rectocèle) et un test d’expulsion au ballonnet permettent de planifier la prise en charge dans les situations les plus habituelles.